Allergan enters non invasive anti-ageing market with VIVITÉ®, a multi purpose skincare product with patented GLX technology

: Parent Category: News and Stories; Posted in: Beauty n Fitness on Friday, 27 September 2013 06:09

Allergan enters non invasive anti-ageing market with VIVITÉ®, a multi purpose skincare product with patented GLX technology
•    VIVITÉ® uses Allergan’s patented GLX technology to deliver glycolic acid and 12 specialized natural ingredients deep into skin to make it younger and fresher.
•    A complete package for multiple beauty purposes, VIVITÉ® not only offers solutions for ageing but also provides specialized therapies for complete skin rejuvenation.

Allergan (NYSE: AGN), the makers of BOTOX® (Botulinum Toxin Type A) and JUVÉDERM™, a company renowned for its special expertise in anti ageing procedures is now entering the non-invasive anti-ageing and skin rejuvenation market with VIVITÉ®, a product that serves a series of purposes in skin replenishment.

To the India market, VIVITÉ®brings a new set of procedures based on Allergan’s patented GLX technology, a path breaking technology in the anti-ageing realm. The product range that provides a package to serve a host of other issues apart from anti-ageing will complement Allergan’s market leader injectable brands Botox and Juvederm.

   Allergan’s path breaking GLX technology uses a process called PARTIAL NEUTRALIZATION that allows high delivery of glycolic compound to the skin like no other product can. This also extends its duration of action in the skin and ensures minimal skin irritation. Glycolic acid helps stimulate the skin’s natural production of hyaluronic acid.

The patented GLX technology delivers glycolic acid and a blend of 12 specialized natural ingredients to the skin in a way no other product or therapy does.

Allergan, which is a market leader in procedures that deliver through injectables, has brought out the VIVITÉ™ skin care line to meet the needs and demands of customers who prefer at- home topical and non invasive solutions to reduce signs of ageing.

Because of its smaller molecular size, glycolic acid is believed to be more effective for skin care than other alpha hydroxy acids. When used correctly, glycolic acid can improve the look and feel of skin and reduce the appearance of fine lines, wrinkles, and brown or age spots.

In GLX Technology, glycolic compound is made to undergo partial neutralization to optimize pH balance to match the natural pH of skin. This allows the glycolic acid to release during an extended period of time to provide the beneﬁts of higher concentrations. The antioxidants in GLX Technology help protect skin from free radicals, which attack and prematurely age skin.

The range of products in this line   include VIVITÉ® Vibrance Therapy; VIVITÉ® Core System; VIVITÉ® Replenish System; and VIVITÉ® Daily Facial Cleanser. The therapies carry a mix of best practices for skincare including exfoliation, antioxidants, along with elements of eye revitalization, night renewal, moisturization and Sunscreen to serve as a multi-purpose and complete skin rejuvenation regime.

VIVITÉ® Vibrance Therapy, which comes with restorative and antioxidant rich cream for brightening and more even skin tone, is not just a product but a 7 in 1 professional skin care therapy which exfoliates, moisturizes, improves skin tone, acts as an antioxidant, anti inflammatory and anti wrinkle agent, and reduces pigmentation, rejuvenating your skin within 8 weeks.

VIVITÉ® Core System on the other hand comprises of exfoliating cleansers, revitalizing eye cream and night renewal facial cream. It contains 4 products which utilize the patented GLX Technology to repair & revitalize your skin within 3 weeks.

The VIVITÉ® range also has no hydroquinone that is believed to have side effects for the skin, including carcinogenic tendencies. The specialized product that delivers what it promises is trusted by leading dermatologists.

About Allergan

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 10,800 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.

Forward-Looking Statements

This press release contains "forward-looking statements," regarding the effectiveness and product availability of VIVITE. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory process challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2010 Form 10-K.